NEUWAY Pharma Extends First Round Financing to € 5.85 Million
(firmenpresse) - Bonn, October 22, 2015 - NEUWAY Pharma announced today the successful closing of a € 3.15 Mio Series A Extension financing round to a total of € 5.85 Million. The lead investor Wellington Partners provided € 2.0 Million of the acquired funds. Life Science Inkubator, Kreditanstalt für Wiederaufbau (KfW) and several private shareholders also participated in the financing round.
Besides the development of the proprietary CNS drug delivery platform, the financial resources allow NEUWAY the production of clinical trial material according to GMP. “I am pleased about the great confidence the investors and shareholders have in our company. Continued funding will accelerate the development of our technology and we will soon be able to start testing with GMP material”, says Dr. Heiko Manninga, co-founder and Managing Director of NEUWAY.
“Solid financial backing will enable NEUWAY to transform itself from a research company to a development company”, comments Dr. Rainer Strohmenger, General Partner at Wellington Partners, “ We believe in broad applicability of the CNS drug delivery platform of NEUWAY and we will do everything to support the company in their further development.”
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.
NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated for the last 4 years and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners.
NEUWAY Pharma GmbH
Ludwig-Erhard-Allee 2
53175 Bonn, Germany
+49(0)228-5227980
Christine Kuhn
kuhn(at)neuway.de
Datum: 29.10.2015 - 05:32 Uhr
Sprache: Deutsch
News-ID 1395300
Anzahl Zeichen: 1224
contact information:
Contact person: Christine Kuhn
Town:
Bonn
Phone: +49(0)228-5227980
Kategorie:
Research & Development
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 29.10.2015
Anmerkungen:
Diese Pressemitteilung wurde bisher 455 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NEUWAY Pharma Extends First Round Financing to € 5.85 Million
"
steht unter der journalistisch-redaktionellen Verantwortung von
NEUWAY Pharma GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
